TORONTO, Oct. 15 /CNW/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has appointed Patrick Terry as its lead strategic advisor for the U.S. commercial launch of ColonSentry(TM), the world's first blood-based test to determine a person's current risk for colorectal cancer. Mr. Terry is one of the co-founders of Genomic Health, a leading molecular diagnostics company.
"Having co-founded one of the most successful molecular diagnostic companies in the U.S., Mr. Terry is the ideal individual to advise GeneNews on its U.S. commercialization strategy," said Dr. Heiner Dreismann, Interim CEO and Lead Director of GeneNews. "Mr. Terry is a pioneer in the field of personalized medicine. His experience growing Genomic Health from a start up to a company with $64 million in revenues will be invaluable as we prepare for U.S. commercialization of our ColonSentry(TM) test in 2009." The Company launched its lead product, the ColonSentry test, in Canada earlier this year.
Mr. Terry is the co-founder and former Director of Consumer Advocacy & Governmental Affairs at Genomic Health. He is also co-founder and former President of the International Genetic Alliance, which focuses on empowering problem solving by networking the consumer movement, centers of excellence, and high technology with patient communities around the world. Mr. Terry has published dozens of peer-reviewed scientific papers, articles, and book chapters in the field of genetics, personalized medicine, and biomedical research. Some of his activities include leadership positions on numerous trade associations, professional societies, corporate boards, and he also sits on a number of U.S. federal advisory bodies.
GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit www.genenews.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
SOURCE GeneNews Limited
For further information: For further information: James Smith, (416) 815-0700 x 229, email@example.com